27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In Alzheimer's disease, the spread of aberrantly phosphorylated tau is an important criterion in the Braak staging of disease severity and correlates with disease symptomatology. 4 key findings →
Participants: 654 Evidence: high
Full summary, score breakdown and related studies → Original source
Among cognitively unimpaired participants with a family history of dementia, changes in cognition and brain MRI outcomes from baseline to year 3 did not differ significantly between those who followed the MIND diet and those who followed the control diet with mild caloric restriction. 5 key findings →
Design: RCT Participants: 604 Evidence: null result
Full summary, score breakdown and related studies → Original source Free full text
Anti-amyloid-ß mAbs attenuate cognitive and functional decline compared with placebo in early AD; whether the magnitude of this effect is clinically important remains uncertain, especially relative to the safety profile of these medications. 5 key findings →
Participants: 15,275 Evidence: high
Full summary, score breakdown and related studies → Original source
General baseline characteristics of the study population were mean (standard deviation) age, 58.1 (8.8) years; 47% women. 5 key findings →
Design: meta-analysis Participants: 1,087 Evidence: high
Full summary, score breakdown and related studies → Original source
The prediction model achieved PPV of 97.7% for amyloid, 96.2% for tau. 119 participants in the full analysis set (70 treatment and 49 placebo) were classified as A+T+. 5 key findings →
Design: post-hoc analysis Participants: 196 Evidence: high
Full summary, score breakdown and related studies → Original source
These findings suggest that a hearing intervention might reduce cognitive change over 3 years in populations of older adults at increased risk for cognitive decline but not in populations at decreased risk for cognitive decline. 5 key findings →
Design: randomized controlled trial Participants: 858 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Robust concordance between CSF biomarkers and amyloid PET visual status was observed (for Aβ42/Aβ40, AUC: 0.90; 95% CI: 0.83-0.97; p < 0.0001), confirming CSF biomarkers as a reliable alternative to amyloid PET in these studies. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
Adults aged 65+ are at highest risk for severe COVID-19 outcomes, and prior to the distribution of vaccines in the U.S., were strongly advised to quarantine at home to reduce risk of infection. 3 key findings →
Design: randomized controlled trial Participants: 156 Evidence: high
Full summary, score breakdown and related studies → Original source
In this clinical trial, older adults with MCI receiving aerobic-resistance exercises with sequential computerized cognitive training significantly improved cognition, although some results were inconsistent. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Among 68 756 unique individuals, analyses included 21 852 East Asian (demographic data not available), 5738 Hispanic (68.2% female; mean [SD] age, 75.4 [8.8] years), 7145 non-Hispanic Black (hereafter referred to as Black) (70.8% female; mean [SD] age, 78.4 [8.2] years), and 34 021 non-Hispanic White (hereafter referred to as White) (59.3% female; mean [SD] age, 77.0 [9.1] years) individuals. 5 key findings →
Design: case-control Participants: 68,756 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Tau accumulation in patients with Alzheimer's disease tracks closely with cognitive decline and plays a role in the later stages of disease progression. 4 key findings →
Design: clinical trial Participants: 108 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The treatment group had no EM after intervention completion (assessed at 3-month follow-up), a significantly lower rate than the control group (treatment = 0%, control = 23.1%, p = 0.010). 3 key findings →
Design: randomized controlled trial Participants: 80 Evidence: high
Full summary, score breakdown and related studies → Original source
Further studies are warranted to develop and refine the specific MIND diet for different populations. 4 key findings →
Design: meta-analysis Participants: 224,049 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline. 2 key findings →
Design: clinical trial Participants: 980 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The intervention did not improve global cognitive performance. 2 key findings →
Design: randomized controlled trial Participants: 819 Evidence: high
Full summary, score breakdown and related studies → Original source
Only RCTs were included in this study; there were eleven studies ( n = 2609 participants) of the Mediterranean diet, seven studies ( n = 313) of the ketogenic diet and one study ( n = 37) of the MIND diet. 4 key findings →
Design: systematic review Participants: 2,609 Evidence: high
Full summary, score breakdown and related studies → Original source
FDA-approved anti-Aβ mabs have a role in slowing disease progression in patients with AD, at the cost of an increased probability of side effects. 3 key findings →
Design: systematic review Participants: 4,471 Evidence: high
Full summary, score breakdown and related studies → Original source
An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration. 5 key findings →
Design: cohort Participants: 1,016 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Good sleep is essential for health, yet associations between sleep and dementia risk remain incompletely understood. 4 key findings →
Design: meta-analysis Participants: 5,946 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. 5 key findings →
Design: meta-analysis Participants: 1,362 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 24 published articles that included 2397 AD and 3242 MCI patients were analysed. 5 key findings →
Design: meta-analysis Participants: 2,397 Evidence: high
Full summary, score breakdown and related studies → Original source
The FDA approved lecanemab for Alzheimer's disease in January 2023 which acts as a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody and is administered intravenously. 5 key findings →
Design: systematic review Participants: 2,729 Evidence: high
Full summary, score breakdown and related studies → Original source
Post-hoc analyses showed that outcomes in the ENGAGE high-dose group were affected by an imbalance in a small number of patients with extremely rapid progression and by lower exposure to the target dose of 10 mg/kg. 4 key findings →
Design: post-hoc analysis Participants: 1,638 Evidence: high
Full summary, score breakdown and related studies → Original source
The enrollment rate was acceptable despite pandemic related challenges (53/60 target recruitment sample). 5 key findings →
Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source
In this meta-analysis, the usage of hearing restorative devices by participants with hearing loss was associated with a 19% decrease in hazards of long-term cognitive decline. 5 key findings →
Design: meta-analysis Participants: 137,484 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →